CAMBRIDGE, UK – November 1 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, is presenting research and preclinical data on its USP30 inhibitor Parkinson’s disease programmes as two posters at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.
Mission Therapeutics’ CNS scientists Dr Paul Thompson, Medical Director, CNS Translational Medicine and Dr Marc Watson. Principal Scientist, CNS will be available to meet during the conference: To arrange a time, email: firstname.lastname@example.org
Details of Poster Presentations:
Poster #759.03/Title: USP30 inhibitors for Parkinson’s disease
Poster #759.04/Title: Targeting USP30 in Parkinson’s iPSC-derived dopamine neurons
Session Title: The Pathogenesis Mechanisms of Mitochondria in Parkinson’s Disease
Session Number: 759
Session Time: Wednesday November 15th, 2017 1.00 pm – 5:00 pm ET
FOR MORE INFORMATION:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 497199
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2020
Westwicke Partners (U.S.)
Tel: +1 339-970-2843
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.
In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.